{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:33:03Z","timestamp":1791495183600,"version":"4.3.4"},"reference-count":301,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"am","delay-in-days":666,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejmech.2022.114785","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:16:46Z","timestamp":1663805806000},"page":"114785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse"],"prefix":"10.1016","volume":"243","author":[{"given":"Md Imdadul H.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Akins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-7113","authenticated-orcid":false,"given":"Hoang V.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114785_bib1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114785_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pharmthera.2013.06.003","article-title":"Delta opioid receptors in brain function and diseases","volume":"140","author":"Chu Sin Chung","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114785_bib3","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel \u03bc-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2015.02.007","article-title":"Nociceptin and the nociceptin receptor in learning and memory","volume":"62","author":"Andero","year":"2015","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114785_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.2042-7158.1954.tb11033.x","article-title":"Synthetic analgesics: stereochemical considerations","volume":"6","author":"Beckett","year":"1954","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib6","article-title":"Opioid receptors in GtoPdb v.2021.3, IUPHAR","volume":"3","author":"Borsodi","year":"2021","journal-title":"BPS Guid. to Pharmacol. CITE."},{"key":"10.1016\/j.ejmech.2022.114785_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/jm00329a013","article-title":"A new concept on the mode of interaction of narcotic analgesics with receptors","volume":"8","author":"Portoghese","year":"1965","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/267495a0","article-title":"Endogenous opioid peptides: multiple agonists and receptors","volume":"267","author":"Lord","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114785_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","article-title":"Kappa opioids and the modulation of pain","volume":"210","author":"Kivell","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S1734-1140(11)70694-6","article-title":"Pharmacological activity of Salvinorin A, the major component of Salvia divinorum","volume":"63","author":"Listos","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2022.114785_bib12","unstructured":"atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions. https:\/\/ir.atai.life\/news-releases\/news-release-details\/atai-launches-revixia-life-sciences-develop-salvinorin-variety (accessed February 28, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0269881119849821","article-title":"Salvindolin elicits opioid system-mediated antinociceptive and antidepressant-like activities","volume":"33","author":"Keasling","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-B","article-title":"Kappa opioid inhibition of morphine and cocaine self-administration in rats","volume":"681","author":"Glick","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0022-3565(24)36769-2","article-title":"Effects of kappa opioids on cocaine self-administration by rhesus monkeys","volume":"282","author":"Negus","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130051016","article-title":"U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking","volume":"144","author":"Schenk","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.ejmech.2022.114785_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2210-12-5","article-title":"Long-acting \u03ba opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity","volume":"12","author":"Munro","year":"2012","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib19","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2022.114785_bib20","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.bmcl.2014.03.040","article-title":"Antagonists of the kappa opioid receptor","volume":"24","author":"Urbano","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/npp.2015.27","article-title":"A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral doses of JDTic","volume":"40","author":"Buda","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib22","article-title":"Alleviation of cocaine withdrawal and pertinent interactions between salvinorin-based antagonists and kappa opioid receptor","author":"Akins","year":"2022","journal-title":"ChemRxiv"},{"key":"10.1016\/j.ejmech.2022.114785_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0304-3959(99)00119-0","article-title":"The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain","volume":"83","author":"Gear","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.npp.1300105","article-title":"Effects of mixed-action \u03ba\/\u03bc opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys","volume":"28","author":"Bowen","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib25","series-title":"Sedation - E-Book: A Guide to Patient Management","author":"Malamed","year":"2009"},{"key":"10.1016\/j.ejmech.2022.114785_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/00325481.2016.1128308","article-title":"Levorphanol use: past, present and future","volume":"128","author":"Gudin","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1213\/ANE.0000000000003360","article-title":"Pharmacological characterization of levorphanol, a G-protein biased opioid analgesic","volume":"128","author":"Le Rouzic","year":"2019","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejmech.2022.114785_bib28","first-page":"7","article-title":"Levorphanol: revisiting an underutilized analgesic","volume":"8","author":"Prommer","year":"2014","journal-title":"Palliat. Care."},{"key":"10.1016\/j.ejmech.2022.114785_bib29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.npp.1300631","article-title":"Effects of the mixed mu\/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men","volume":"30","author":"Mello","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.105","article-title":"Engineering therapeutic antibodies targeting G-protein\u2013coupled receptors","volume":"48","author":"Jo","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114785_bib32","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/mol.114.096503","article-title":"A novel method for analyzing extremely biased agonism at G protein\u2013coupled receptors","volume":"87","author":"Stahl","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib33","article-title":"Agonist-promoted phosphorylation and internalization of the kappa opioid receptor in mouse brains: lack of connection with conditioned place aversion","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib34","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2022.114785_bib35","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3390\/molecules25184257","article-title":"Biased opioid ligands","volume":"25","author":"Faouzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114785_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3389\/fnins.2020.00765","article-title":"Evaluation of biased and balanced salvinorin A analogs in preclinical models of pain","volume":"14","author":"Paton","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib37","doi-asserted-by":"crossref","first-page":"24328","DOI":"10.1074\/jbc.273.38.24328","article-title":"Selective interference of \u03b2-arrestin 1 with \u03ba and \u03b4 but not \u03bc opioid receptor\/G protein coupling","volume":"273","author":"Cheng","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib38","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.bbamcr.2016.07.009","article-title":"Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel \u03b2-arrestin-2\u2013biased pathway","volume":"1863","author":"Liu","year":"2016","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173377","article-title":"Sex- and \u03b2-arrestin-dependent effects of kappa opioid receptor-mediated ethanol consumption","volume":"216","author":"French","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2022.114785_bib40","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2022.114785_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/can.2016.0037","article-title":"Cannabinoid CB 1 and CB 2 receptor signaling and bias","volume":"2","author":"Ibsen","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FJC.0000000000000356","article-title":"G protein\u2013coupled receptor biased agonism","volume":"67","author":"Hodavance","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fphar.2019.00407","article-title":"A review of the therapeutic potential of recently developed G protein-biased kappa agonists","volume":"10","author":"Mores","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0278-5846(82)80130-9","article-title":"U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists","volume":"6","author":"Von Voigtlander","year":"1982","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114785_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)33422-1","article-title":"U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist","volume":"224","author":"Vonvoigtlander","year":"1983","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib46","first-page":"134","article-title":"U-50,488 (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]-benzeneacetamide): prototype for a new class of opioid analgesics","volume":"23","author":"VonVoigtlander","year":"1981","journal-title":"Pharmacologist"},{"key":"10.1016\/j.ejmech.2022.114785_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-2999(85)90431-5","article-title":"[3H]U-69593 a highly selective ligand for the opioid \u03ba receptor","volume":"109","author":"Lahti","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3565(25)21012-6","article-title":"Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid","volume":"246","author":"Vonvoigtlander","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib49","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1021\/jm301258w","article-title":"Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective \u03ba opioid receptor agonist","volume":"55","author":"Spetea","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejphar.2015.05.054","article-title":"Intrinsic relative activities of \u03ba opioid agonists in activating G\u03b1 proteins and internalizing receptor: differences between human and mouse receptors","volume":"761","author":"DiMattio","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib51","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.ejmech.2022.114785_bib52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0028-3908(88)90052-4","article-title":"U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites","volume":"27","author":"Clark","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib53","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/0024-3205(82)90132-1","article-title":"Properties of a selective kappa agonist, U-50,488H","volume":"31","author":"Lahti","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2004.04.043","article-title":"Contralateral, ipsilateral and bilateral treatments with the \u03ba-opioid receptor agonist U-50,488H in mononeuropathic rats","volume":"494","author":"Bileviciute-Ljungar","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(88)90595-X","article-title":"Analgesia produced by centrally administered DAGO, DPDPE and U50488H in the formalin test","volume":"153","author":"Calcagnetti","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-3565(25)24991-6","article-title":"U50,488, a highly selective kappa opioid: anticonvulsant profile in rats","volume":"237","author":"Tortella","year":"1986","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/rheumatology\/kei156","article-title":"Anti-inflammatory effects of contralateral administration of the \u03ba-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis","volume":"45","author":"Bileviciute-Ljungar","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2022.114785_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50,488, a \u03ba opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)38497-1","article-title":"Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities","volume":"268","author":"France","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114785_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0024-3205(88)90638-8","article-title":"Interaction of U-69,593 with \u03bc-, \u2202- and k-opioid binding sites and its analgesic and intestinal effects in rats","volume":"42","author":"La Regina","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0091-3057(98)00124-5","article-title":"Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat","volume":"61","author":"Craft","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2022.114785_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.forsciint.2015.01.038","article-title":"Salvinorin A content in legal high products of Salvia divinorum sold in Mexico","volume":"249","author":"Hern\u00e1ndez-Bello","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.ejmech.2022.114785_bib64","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1039\/p19820002505","article-title":"Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae)","volume":"1","author":"Ortega","year":"1982","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.ejmech.2022.114785_bib65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.lfs.2005.09.008","article-title":"Psychopharmacology of the hallucinogenic sage Salvia divinorum","volume":"78","author":"Prisinzano","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib66","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"A potent naturally occurring nonnitrogenous opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114785_bib67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein\u2013biased \u03ba -opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib68","first-page":"452","article-title":"Therapeutic potential of salvinorin A and its analogues in various neurological disorders","volume":"9","author":"Cichon","year":"2022","journal-title":"Transl. Perioper. Pain Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ijnp\/pyab063","article-title":"The kappa opioid receptor and the sleep of reason: cortico-subcortical imbalance following salvinorin-A","volume":"25","author":"Ona","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib70","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.bmcl.2018.03.029","article-title":"A review of salvinorin analogs and their kappa-opioid receptor activity","volume":"28","author":"Roach","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100684","article-title":"6,5\u2010Fused ring, C2\u2010salvinorin ester, dual kappa and mu opioid receptor agonists as analgesics devoid of anxiogenic effects","volume":"17","author":"Akins","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114785_bib72","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.bmcl.2005.03.113","article-title":"Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2)","volume":"15","author":"Beguin","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib73","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1016\/j.bmcl.2006.05.093","article-title":"Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18)","volume":"16","author":"Beguin","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib74","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/jpet.107.129023","article-title":"N-methylacetamide analog of salvinorin A: a highly potent and selective -opioid receptor agonist with oral efficacy","volume":"324","author":"Beguin","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib75","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1039\/c1md00192b","article-title":"Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A","volume":"2","author":"Prevatt-Smith","year":"2011","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2022.114785_bib76","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bmc.2007.10.067","article-title":"Standard protecting groups create potent and selective \u03ba opioids: salvinorin B alkoxymethyl ethers","volume":"16","author":"Munro","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.114.214239","article-title":"Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome","volume":"350","author":"Sa\u0142aga","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib78","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.bmc.2012.02.040","article-title":"Semisynthetic neoclerodanes as kappa opioid receptor probes","volume":"20","author":"Lovell","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib79","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1016\/j.bmcl.2007.09.050","article-title":"Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position","volume":"17","author":"Holden","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib80","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00213-017-4637-2","article-title":"The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and \u03b2-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects","volume":"234","author":"Ewald","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib81","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/ejp.1002","article-title":"The analgesic and anti-inflammatory effects of Salvinorin A analogue \u03b2-tetrahydropyran Salvinorin B in mice","volume":"21","author":"Paton","year":"2017","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib82","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1021\/jm501521d","article-title":"Synthesis and \u03ba-opioid receptor activity of furan-substituted salvinorin A analogues","volume":"57","author":"Riley","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib83","first-page":"21","article-title":"The use of \u03b2-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes","volume":"3","author":"Furchgott","year":"1966","journal-title":"Adv. Drug Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib85","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1039\/D1MD00041A","article-title":"Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors","volume":"12","author":"De Neve","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib86","first-page":"141","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A review of the properties of spiradoline: a potent and selective k-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejmech.2022.114785_bib88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.113.089649","article-title":"Identification of novel functionally selective \u03ba -opioid receptor scaffolds","volume":"85","author":"White","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib89","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","article-title":"Interactions between kappa opioid agonists and cocaine: preclinical studies","volume":"909","author":"Mello","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib90","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0022-3565(25)22683-0","article-title":"Diuretic actions in man of a selective kappa opioid agonist: U-62,066E","volume":"240","author":"Peters","year":"1987","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib91","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1991.tb03960.x","article-title":"Mechanism of diuretic action of spiradoline (U-62066E)-a kappa opioid receptor agonist in the human","volume":"32","author":"Rimoy","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib92","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/bph.13854","article-title":"Selective \u03ba receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice","volume":"174","author":"Spetea","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","article-title":"Structurally related kappa opioid receptor agonists with substantial differential signaling bias: neuroendocrine and behavioral effects in C57BL6 mice","volume":"21","author":"Dunn","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib94","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/acs.jmedchem.7b00981","article-title":"Highly potent and selective new diphenethylamines interacting with the \u03ba-opioid receptor: synthesis, pharmacology, and structure\u2013activity relationships","volume":"60","author":"Erli","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib95","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1021\/jm010095v","article-title":"Transformation of a \u03ba-opioid receptor antagonist to a \u03ba-agonist by transfer of a guanidinium group from the 5\u2018- to 6\u2018-position of naltrindole","volume":"44","author":"Sharma","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib96","doi-asserted-by":"crossref","first-page":"27050","DOI":"10.1074\/jbc.C112.387332","article-title":"6\u2032-Guanidinonaltrindole (6\u2032-GNTI) is a G protein-biased \u03ba-opioid receptor agonist that inhibits arrestin recruitment","volume":"287","author":"Rives","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib97","series-title":"The Organic Chemistry of Drug Design and Drug Action","author":"Silverman","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114785_bib98","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsps.2016.07.002","article-title":"An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice","volume":"25","author":"Salahudeen","year":"2017","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.ejmech.2022.114785_bib99","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1073\/pnas.0501112102","article-title":"A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers","volume":"102","author":"Waldhoer","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114785_bib100","doi-asserted-by":"crossref","first-page":"22387","DOI":"10.1074\/jbc.M113.476234","article-title":"Functional selectivity of 6\u2032-guanidinonaltrindole (6\u2032-GNTI) at \u03ba-opioid receptors in striatal neurons","volume":"288","author":"Schmid","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib101","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G\u2010protein biased partial \u03ba opioid receptor agonist 6\u2032\u2010GNTI blocks hippocampal paroxysmal discharges without inducing aversion","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib102","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0040-4020(01)97243-6","article-title":"Isolement et analyse structurale du collybolide, nouveau sesquiterpene extrait de Collybia maculata alb. et sch. ex fries (basidiomycetes)","volume":"30","author":"Bui","year":"1974","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2022.114785_bib103","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1073\/pnas.1521825113","article-title":"Collybolide is a novel biased agonist of \u03ba-opioid receptors with potent antipruritic activity","volume":"113","author":"Gupta","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114785_bib104","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1021\/acscentsci.2c00442","article-title":"Asymmetric syntheses of (+)- and (\u2212)-Collybolide enable reevaluation of kappa -opioid receptor agonism","volume":"8","author":"Shevick","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib105","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1021\/bi900605n","article-title":"Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the \u03ba-opioid receptor","volume":"48","author":"Yan","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114785_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104748","article-title":"Kappa opioid receptors internalization is protective against oxygen-glucose deprivation through \u03b2-arrestin activation and Akt-mediated signaling pathway","volume":"137","author":"Xu","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2022.114785_bib107","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2020.00188","article-title":"Functional selectivity and antinociceptive effects of a novel KOPr agonist","volume":"11","author":"Bedini","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib108","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/jm0498811","article-title":"Synthesis and evaluation of the affinity toward \u03bc-opioid receptors of atypical, lipophilic ligands based on the sequence c [-Tyr-Pro-Trp-Phe-Gly-]","volume":"47","author":"Cardillo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib109","doi-asserted-by":"crossref","first-page":"9255","DOI":"10.1021\/acs.jmedchem.6b00420","article-title":"Versatile picklocks to access all opioid receptors: tuning the selectivity and functional profile of the cyclotetrapeptide c[phe- <scp>d<\/scp> -Pro-Phe-Trp] (CJ-15,208)","volume":"59","author":"De Marco","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib110","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1096\/fasebj.27.1_supplement.1171.3","article-title":"Development of biased agonists at the kappa opioid receptor","volume":"27","author":"Phillips","year":"2013","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2022.114785_bib111","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib112","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1248\/cpb.46.366","article-title":"Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan, Chem","volume":"46","author":"Nagase","year":"1998","journal-title":"Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2022.114785_bib113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2009.06.016","article-title":"Nalfurafine prevents 5\u2032-guanidinonaltrindole- and compound 48\/80-induced spinal c-fos expression and attenuates 5\u2032-guanidinonaltrindole-elicited scratching behavior in mice","volume":"163","author":"Inan","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2022.114785_bib114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","article-title":"Effects of a newly synthesized \u03ba-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats","volume":"161","author":"Mori","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib116","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib117","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib118","first-page":"185","article-title":"Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist","volume":"30","author":"Nakao","year":"2010","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"10.1016\/j.ejmech.2022.114785_bib119","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejmech.2022.114785_bib120","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1021\/jm00067a004","article-title":"A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines","volume":"36","author":"Naylor","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib121","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.1532-2149.2011.00022.x","article-title":"Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes","volume":"16","author":"Brissett","year":"2012","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib122","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/jm301543e","article-title":"Orvinols with mixed kappa\/mu opioid receptor agonist activity","volume":"56","author":"Greedy","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib123","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.120.000134","article-title":"Strategies for developing \u03ba opioid receptor agonists for the treatment of pain with fewer side effects","volume":"375","author":"Paton","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib124","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/np8005748","article-title":"Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse","volume":"72","author":"Prisinzano","year":"2009","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2022.114785_bib126","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.lfs.2013.09.016","article-title":"Novel fentanyl-based dual \u03bc\/\u03b4-opioid agonists for the treatment of acute and chronic pain","volume":"93","author":"Podolsky","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib127","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/jo01092a012","article-title":"Structures related to morphine. XII. (+\/-)-20 -Hydroxy5,9-dimethyl-2-phenethyl-6,7-benzomorphan (NIH 7519) and its optical forms","volume":"24","author":"May","year":"1959","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/jo01084a655","article-title":"A new potent synthetic analgesic","volume":"24","author":"May","year":"1959","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/jo01092a011","article-title":"Structures related to morphine. XI. Analogs and a diastereomer of 20 -Hydroxy-2,5,9-trimethyl-6,7-benzomorphan","volume":"24","author":"May","year":"1959","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/184451a0","article-title":"Identification of phenazocine, a potent new analgesic","volume":"184","author":"Clarke","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114785_bib131","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/jm00332a001","article-title":"Pentazocine. 1 strong analgesics and analgesic antagonists in the benzomorphan series 2","volume":"7","author":"Archer","year":"1964","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib132","first-page":"382","article-title":"Clinical trial of two analgesics: WIN 14,098 and ethoheptazine, fed","volume":"18","author":"De Kornfeld","year":"1959","journal-title":"SAVE Proc."},{"key":"10.1016\/j.ejmech.2022.114785_bib133","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/gut.12.1.51","article-title":"Double-blind clinical trial of the analgesic effects of phenazocine hydrobromide (Narphen) compared with morphine sulphate in patients with acute abdominal pain","volume":"12","author":"Hopton","year":"1971","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2022.114785_bib134","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cpt1961218","article-title":"VI. Comparative respiratory depressant activity of phenazocine and morphine","volume":"2","author":"Papadopoulos","year":"1961","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114785_bib135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bmcl.2008.10.134","article-title":"Syntheses and opioid receptor binding properties of carboxamido-substituted opioids","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib136","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-3565(25)26704-0","article-title":"Some narcotic antagonists in the benzomorphan series","volume":"143","author":"Harris","year":"1964","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib137","first-page":"37237","article-title":"Quotas - 2013, fed","volume":"78","year":"2013","journal-title":"Regist"},{"key":"10.1016\/j.ejmech.2022.114785_bib138","series-title":"Versions 2 and 3. The Read Codes Drug and Appliance Dictionary","year":"2001"},{"key":"10.1016\/j.ejmech.2022.114785_bib139","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jama.1964.03070040082033","article-title":"Pentazocine vs morphine","volume":"189","author":"Cass","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114785_bib140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbr.2016.06.019","article-title":"Estrogen facilitates and the kappa and mu opioid receptors mediate antinociception produced by intrathecal (\u2212)-pentazocine in female rats","volume":"312","author":"Robinson","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib141","doi-asserted-by":"crossref","DOI":"10.1186\/1744-8069-7-23","article-title":"(\u2212)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in \u03bc-opioid receptor knockout mice","volume":"7","author":"Ide","year":"2011","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb06672.x","article-title":"Partial opioids: medications for the treatment of pain and drug abuse","volume":"909","author":"Bidlack","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib143","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.111.179879","article-title":"Pentazocine-induced antinociception is mediated mainly by \u03bc-opioid receptors and compromised by \u03ba-opioid receptors in mice","volume":"338","author":"Shu","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib144","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1964.03070030021006","article-title":"Pentazocine\u2014 a new nonaddicting analgesic. Preliminary single-blind study","volume":"189","author":"Sadove","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114785_bib145","series-title":"Pentazocine, in: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.ejmech.2022.114785_bib146","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.1983.03330370005002","article-title":"Talwin 50 reformulated to avert \u201cT's and blues\u201d abuse","volume":"249","author":"Carlson","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114785_bib147","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/bja\/40.5.341","article-title":"The sedative properties of pentazocine (Fortral)","volume":"40","author":"Norris","year":"1968","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2022.114785_bib148","first-page":"195","article-title":"[Sosegon (pentazocine) in anesthesia]","volume":"25","author":"Taberna Esparza","year":"1978","journal-title":"Rev. Esp. Anestesiol. Reanim."},{"key":"10.1016\/j.ejmech.2022.114785_bib149","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1532-5415.2009.02306.x","article-title":"Nonprescription use of pain relievers by middle-aged and elderly community-living adults: national survey on drug use and health","volume":"57","author":"Blazer","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejmech.2022.114785_bib150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12663-013-0595-3","article-title":"A study of promethazine hydrochloride and pentazocine intramuscular sedation along with 2 % lidocaine hydrochloride and adrenaline and comparison to placebo along with 2 % lidocaine hydrochloride and adrenaline for surgical extraction of mandibular third","volume":"14","author":"Lalfamkima","year":"2015","journal-title":"J. Maxillofac. Oral Surg."},{"key":"10.1016\/j.ejmech.2022.114785_bib151","series-title":"Drugs of Abuse","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114785_bib152","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1073\/pnas.77.6.3691","article-title":"Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia","volume":"77","author":"Pasternak","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114785_bib153","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0014-827X(02)01243-0","article-title":"Diazabicyclononanones, a potent class of kappa opioid analgesics","volume":"57","author":"Holzgrabe","year":"2002","journal-title":"Farm"},{"key":"10.1016\/j.ejmech.2022.114785_bib154","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1021\/jm401290y","article-title":"Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors","volume":"56","author":"Provencher","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0960-894X(01)00014-2","article-title":"8-Carboxamidocyclazocine analogues","volume":"11","author":"Wentland","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib156","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/jpet.302.1.374","article-title":"8-Carboxamidocyclazocine: a long-acting, novel benzomorphan","volume":"302","author":"Bidlack","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib157","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2004.10.051","article-title":"Effects of the mixed-action \u03ba\/\u03bc opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys","volume":"506","author":"Stevenson","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib158","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1016\/j.bmcl.2012.10.081","article-title":"Redefining the structure\u2013activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1\u2032-biphenyl]-4-ylethyl) analogues of 8-CAC","volume":"22","author":"Wentland","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib159","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/jm9903343","article-title":"Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed \u03ba agonists and \u03bc agonists\/antagonists as potential pharmacotherapeutics for cocaine dependence","volume":"43","author":"Neumeyer","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib160","series-title":"N-substituted-14-hydroxydihydronormorphines","author":"Pachter","year":"1968"},{"key":"10.1016\/j.ejmech.2022.114785_bib161","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/jm061327z","article-title":"Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at \u03bc, \u03b4, and \u03ba opioid receptors","volume":"50","author":"Peng","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib162","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10928-007-9076-y","article-title":"A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain","volume":"35","author":"Kshirsagar","year":"2008","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejmech.2022.114785_bib163","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejmech.2019.06.028","article-title":"A novel finding of nalbuphine-6-glucuronide, an active opiate metabolite, possessing potent antinociceptive effects: synthesis and biological evaluation","volume":"178","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib164","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2019.02.010","article-title":"MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats","volume":"150","author":"Atigari","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib165","series-title":"Cancer Pain Assessment and Management","author":"Bruera","year":"2009"},{"key":"10.1016\/j.ejmech.2022.114785_bib166","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ml500116x","article-title":"Discovery of spiro[cyclohexane-dihydropyrano[3,4- b ]indole]-amines as potent NOP and opioid receptor agonists","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib167","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/ml500117c","article-title":"Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib168","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib169","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ALN.0000000000001530","article-title":"Opioid-type respiratory depressant side effects of cebranopadol in rats are limited by its nociceptin\/orphanin FQ peptide receptor agonist activity","volume":"126","author":"Linz","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2022.114785_bib170","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.444","article-title":"Synergistic interaction between the agonism of cebranopadol at nociceptin\/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model","volume":"6","author":"Christoph","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2022.114785_bib171","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial","volume":"158","author":"Christoph","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib172","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","article-title":"Cebranopadol, a novel first-in-class Analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks","volume":"58","author":"Koch","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ejmech.2022.114785_bib173","series-title":"Congress, the Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic","author":"116th","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114785_bib174","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12094-007-0057-9","article-title":"Oxycodone: a pharmacological and clinical review","volume":"9","author":"Ord\u00f3\u00f1ez Gallego","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2022.114785_bib175","article-title":"Prescription opioids","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114785_bib176","series-title":"Sacklers and Purdue Pharma Reach New Deal with States over Opioids","author":"Hoffman","year":"2022"},{"key":"10.1016\/j.ejmech.2022.114785_bib177","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1021\/acs.jmedchem.8b01136","article-title":"Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias","volume":"61","author":"Kennedy","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib178","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0022-3565(25)24717-6","article-title":"Interaction of trimebutine and Jo-1196 (fedotozine) with opioid receptors in the canine ileum","volume":"257","author":"Allescher","year":"1991","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib179","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/BF02087560","article-title":"Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia","volume":"39","author":"Fraitag","year":"1994","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib180","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/BF02209014","article-title":"Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome","volume":"40","author":"Dapoigny","year":"1995","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib181","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0016-5085(99)70226-X","article-title":"The \u03ba agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome","volume":"116","author":"Delvaux","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2022.114785_bib182","unstructured":"DrugBank Online, Levallorphan: Uses, Interactions, Mechanism of Action. https:\/\/go.drugbank.com\/drugs\/DB00504 (accessed June 30, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib183","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00213-022-06125-5","article-title":"Treatment of opioid overdose: current approaches and recent advances","volume":"239","author":"Britch","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib184","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/bmj.2.5156.859","article-title":"Use of premixed pethidine and antagonists in obstetrical analgesia; with special reference to cases in which levallorphan was used","volume":"2","author":"Bullough","year":"1959","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114785_bib185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5694\/j.1326-5377.1962.tb20494.x","article-title":"An evaluation of a combination of pethidine and levallorphan (\u201cpethilorfan\u201d) in labour","volume":"49","author":"Williams","year":"1962","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2022.114785_bib186","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jog.13850","article-title":"Safety and efficacy of a combination of pethidine and levallorphan for pain relief during labor: an observational study","volume":"45","author":"Kinugasa","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib187","doi-asserted-by":"crossref","first-page":"940","DOI":"10.31729\/jnma.3905","article-title":"Butorphanol in labour analgesia","volume":"56","author":"Yadav","year":"2018","journal-title":"J. Nepal Med. Assoc. JNMA"},{"key":"10.1016\/j.ejmech.2022.114785_bib188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0376-8716(98)00104-5","article-title":"Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine","volume":"53","author":"Greenwald","year":"1998","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejmech.2022.114785_bib189","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/npp.1993.6","article-title":"The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys","volume":"8","author":"Mello","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib190","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1016\/j.bmcl.2008.07.054","article-title":"Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors","volume":"18","author":"Fulton","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib191","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1021\/acschemneuro.6b00075","article-title":"6\u03b2-N-Heterocyclic substituted naltrexamine derivative BNAP: a peripherally selective mixed MOR\/KOR ligand","volume":"7","author":"Williams","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib192","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3389\/fphar.2018.01002","article-title":"In vitro and in vivo pharmacological activities of 14-O-phenylpropyloxymorphone, a potent mixed mu\/delta\/kappa-opioid receptor agonist with reduced constipation in mice","volume":"9","author":"Lattanzi","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib193","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/jm8015552","article-title":"Mixed \u03ba\/\u03bc opioid receptor agonists: the 6\u03b2-naltrexamines","volume":"52","author":"Cami-Kobeci","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib194","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1021\/jm048963m","article-title":"Neoclerodane diterpenes as a novel scaffold for \u03bc opioid receptor ligands","volume":"48","author":"Harding","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib195","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1021\/jm701162g","article-title":"Herkinorin analogues with differential \u03b2-arrestin-2 interactions","volume":"51","author":"Tidgewell","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib196","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2011.10.026","article-title":"Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology","volume":"121","author":"Lamb","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejmech.2022.114785_bib197","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1111\/bph.13212","article-title":"Salvinorin A analogues PR-37 and PR-38 attenuate compound 48\/80-induced itch responses in mice","volume":"172","author":"Salaga","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib198","first-page":"1221","article-title":"Antinociception produced by ADL 10-0101, a novel peripheral kappa opioid receptor agonist, in models of inflammatory hyperalgesia","volume":"25","author":"Gottshall","year":"1999","journal-title":"Soc. Neurosci. Abstr."},{"key":"10.1016\/j.ejmech.2022.114785_bib199","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0960-894X(01)80179-7","article-title":"EMD 61 753 as a favourable representative of structurally novel arylacetamido-type K opiate receptor agonists","volume":"4","author":"Gottschlich","year":"1994","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0960-894X(96)00615-4","article-title":"Trans N-Methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] cycloprop-2-ene-1-carboxamides: novel lipophilic kappa opioid agonists, Bioorg","volume":"7","author":"Sabin","year":"1997","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib201","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00000542-200106000-00018","article-title":"Analgesic and antiinflammatory effects of two novel \u03ba-opioid peptides","volume":"94","author":"Binder","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2022.114785_bib202","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2008.01.011","article-title":"Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral \u03ba-opioid receptors","volume":"583","author":"Vanderah","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-3959(01)00398-0","article-title":"Effect of kappa opioid agonists on visceral nociception induced by uterine cervical distension in rats","volume":"96","author":"Sandner-Kiesling","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcpt.12404","article-title":"Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?","volume":"41","author":"Albert-Vartanian","year":"2016","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib205","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s00125-006-0397-y","article-title":"Kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats","volume":"49","author":"Jolivalt","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2022.114785_bib206","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0304-3959(99)00158-X","article-title":"Lack of cross-tolerance between the antinociceptive effects of systemic morphine and asimadoline, a peripherally-selective \u03ba-opioid agonist, in CCI-neuropathic rats","volume":"83","author":"Walker","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3959(02)00259-2","article-title":"Analgesia from a peripherally active \u03ba-opioid receptor agonist in patients with chronic pancreatitis","volume":"101","author":"Eisenach","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2022.114785_bib208","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1208\/s12248-009-9105-4","article-title":"Peptide kappa opioid receptor ligands: potential for drug development","volume":"11","author":"Aldrich","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2022.114785_bib209","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/jm500940q","article-title":"Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted \u03ba-opioid receptor agonists","volume":"57","author":"Bourgeois","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib210","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1476-5381.1994.tb17142.x","article-title":"A pharmacological profile of the novel, peripherally-selective k-opioid receptor agonist, EMD 61753","volume":"113","author":"Barber","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib211","series-title":"Asimadoline Investigators Brochure. Version 8","year":"2010"},{"key":"10.1016\/j.ejmech.2022.114785_bib212","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1517\/13543784.2010.515209","article-title":"Asimadoline in the treatment of irritable bowel syndrome","volume":"19","author":"Mangel","year":"2010","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114785_bib213","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2007.06.034","article-title":"Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat","volume":"573","author":"Caram-Salas","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib214","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1476-5381.1989.tb11911.x","article-title":"ICI 204448: a kappa-opioid agonist with limited access to the CNS","volume":"96","author":"Shaw","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib215","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/cn200128x","article-title":"Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy","volume":"3","author":"Frankowski","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib216","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1021\/acschemneuro.5b00092","article-title":"Structure\u2013activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1\/2 phosphorylation while preserving G protein over \u03b2Arrestin2 signaling bias","volume":"6","author":"Lovell","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib217","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","article-title":"Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys","volume":"237","author":"Huskinson","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib218","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s00213-021-05965-x","article-title":"The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats","volume":"238","author":"Zamarripa","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173394","article-title":"The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys","volume":"217","author":"Huskinson","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2022.114785_bib220","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.tem.2020.08.005","article-title":"Letter biased opioid receptor ligands: gain without pain","volume":"31","author":"Beck","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2022.114785_bib221","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0079-6123(07)63015-5","article-title":"Opioid systems in the dentate gyrus","volume":"163","author":"Drake","year":"2007","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib222","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/nn1804","article-title":"Dynorphin A activates bradykinin receptors to maintain neuropathic pain","volume":"9","author":"Lai","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114785_bib223","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(83)90481-8","article-title":"Studies in vivo with dynorphin-(1\u20139): analgesia but not gastrointestinal effects following intrathecal administration to mice","volume":"91","author":"Porreca","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib224","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1074\/jbc.273.30.18848","article-title":"Selective ligands for the \u03bc, \u03b4, and \u03ba opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library","volume":"273","author":"Dooley","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib225","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.104.065391","article-title":"FE200041 (d-Phe-d-Phe-d-Nle-d-Arg-NH 2): A peripheral efficacious \u03ba opioid agonist with unprecedented selectivity","volume":"310","author":"Vanderah","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib226","first-page":"186","article-title":"Novel peripheral peptidic kappa agonists","author":"Rivi\u00e8re","year":"1999","journal-title":"Acta Neurobiol. Exp."},{"key":"10.1016\/j.ejmech.2022.114785_bib227","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0705763","article-title":"Peripheral kappa-opioid agonists for visceral pain","volume":"141","author":"Rivi\u00e8re","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib228","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ALN.0b013e3181af6356","article-title":"Analgesic efficacy of peripheral \u03ba-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model","volume":"111","author":"Arendt-Nielsen","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejmech.2022.114785_bib229","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874104501307010016","article-title":"Development of a peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain","volume":"7","author":"Hughes","year":"2013","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.ejmech.2022.114785_bib230","doi-asserted-by":"crossref","DOI":"10.19080\/JPCR.2017.02.555588","article-title":"CR845 (difelikefalin), A kappa receptors agonist in phase III by CARA therapeutics: a case of \u201cspin\u201d in scientific writing?","volume":"2","author":"Hesselink","year":"2017","journal-title":"J. Pharmacol. Clin. Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib231","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib232","doi-asserted-by":"crossref","DOI":"10.19080\/JAICM.2017.03.555620","article-title":"Kappa receptors agonist in postoperative pain","volume":"3","author":"Keppel Hesselink","year":"2017","journal-title":"J. Anesth. Intensive Care Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib233","series-title":"Cara Therapeutics Inc., Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of KORSUVATM (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients","year":"2021"},{"key":"10.1016\/j.ejmech.2022.114785_bib234","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/acsmedchemlett.0c00287","article-title":"Discovery of SHR0687, a highly potent and peripheral nervous system-restricted KOR agonist","volume":"11","author":"Li","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib235","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","article-title":"A randomized proof-of-mechanism trial applying the \u201cfast-fail\u201d approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia","volume":"26","author":"Krystal","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114785_bib236","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1124\/jpet.113.206086","article-title":"Physical presence of nor-binaltorphimine in mouse brain over 21 Days after a single administration corresponds to its long-lasting antagonistic effect on \u03ba -opioid receptors","volume":"346","author":"Patkar","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib237","doi-asserted-by":"crossref","first-page":"E704","DOI":"10.1208\/aapsj070371","article-title":"Kappa opioid antagonists: past successes and future prospects","volume":"7","author":"Metcalf","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2022.114785_bib238","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1021\/jm00349a016","article-title":"Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites","volume":"25","author":"Erez","year":"1982","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib239","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0024-3205(85)90202-4","article-title":"TENA, a selective kappa opioid receptor antagonist","volume":"36","author":"Portoghese","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/jm00385a002","article-title":"Bimorphinans as highly selective, potent .kappa. opioid receptor antagonists","volume":"30","author":"Portoghese","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib241","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2022.114785_bib242","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(25)21011-4","article-title":"Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays","volume":"246","author":"Takemori","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib243","first-page":"815","article-title":"Nor-binaltorphimine: an ultra-long acting kappa-opioid antagonist in pigeons","volume":"6","author":"Jewett","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib244","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-3565(25)11434-1","article-title":"Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick Test1","volume":"260","author":"Horan","year":"1992","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-2999(92)90055-9","article-title":"Long term \u03ba-opioid receptor blockade following nor-binaltorphimine","volume":"215","author":"Jones","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib246","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02245071","article-title":"Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on \u03ba-opioid agonists in the mouse writhing assay","volume":"115","author":"Broadbear","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib247","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0022-3565(25)39577-7","article-title":"Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys","volume":"267","author":"Butelman","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib248","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0022-3565(24)35216-4","article-title":"Intracisternal nor-binaltorphimine distinguishes central and peripheral \u03ba-opioid antinociception in rhesus monkeys","volume":"291","author":"Ko","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib249","first-page":"360","article-title":"Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys, Addict","volume":"21","author":"Hutsell","year":"2016","journal-title":"Biol."},{"key":"10.1016\/j.ejmech.2022.114785_bib250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuropharm.2011.06.014","article-title":"Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats","volume":"62","author":"Chartoff","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib251","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2015.01.008","article-title":"The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats","volume":"283","author":"Kelsey","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib252","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/jm00053a025","article-title":"A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic .kappa. address element to the .delta. antagonist, natrindole: 5\u2019-[(N2-alkylamidino)methyl]naltrindole derivatives as a novel class of .kappa. opioid receptor antagon","volume":"36","author":"Olmsted","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib253","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(00)00208-9","article-title":"5\u2032-Guanidinonaltrindole, a highly selective and potent \u03ba-opioid receptor antagonist","volume":"396","author":"Jones","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib254","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00213-002-1038-x","article-title":"Kappa opioid antagonist effects of the novel kappa antagonist 5?-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys","volume":"163","author":"Negus","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib255","doi-asserted-by":"crossref","first-page":"29803","DOI":"10.1074\/jbc.M705540200","article-title":"Long-acting \u03ba opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating C-jun N-terminal kinase","volume":"282","author":"Bruchas","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib256","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070701","article-title":"Selective \u03ba opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters","volume":"8","author":"Munro","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114785_bib257","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1021\/jm015521r","article-title":"Identification of the first trans -(3 R ,4 R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid \u03ba receptor antagonist activity","volume":"44","author":"Thomas","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib258","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1021\/jm030094y","article-title":"Identification of (3 R)-7-Hydroxy- N -((1 S)-1-{[(3 R ,4 R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid \u03ba receptor antagonist","volume":"46","author":"Thomas","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib259","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2004.08.028","article-title":"Pharmacological properties of JDTic: a novel \u03ba-opioid receptor antagonist","volume":"501","author":"Carroll","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib260","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.107.127415","article-title":"Anxiolytic-like effects of \u03ba-opioid receptor antagonists in models of unlearned and learned fear in rats","volume":"323","author":"Knoll","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib261","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2022.114785_bib262","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejmech.2022.114785_bib263","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2005.09.013","article-title":"Effects of JDTic, a selective \u03ba-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model","volume":"524","author":"Carroll","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib264","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of \u03ba opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib265","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41386-018-0015-y","article-title":"Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders","volume":"43","author":"Domi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib266","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1021\/jm050105i","article-title":"[ N \u03b1 -BenzylTyr 1 , c yclo (d -asp 5 ,dap 8)]- dynorphin A-(1\u221211)NH 2 cyclized in the \u201caddress\u201d domain is a novel \u03ba-opioid receptor antagonist","volume":"48","author":"Patkar","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib267","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1021\/jm900715m","article-title":"The effects of C-terminal modifications on the opioid activity of [ N -BenzylTyr 1]dynorphin A-(1\u221211) analogues","volume":"52","author":"Patkar","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib268","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.0910180106","article-title":"Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action","volume":"106","author":"Aldrich","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114785_bib269","series-title":"Probe Reports from the NIH Molecular Libraries Program","article-title":"Optimization and characterization of an opioid kappa receptor (OPRK1) antagonist","author":"Guerrero","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114785_bib270","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","article-title":"Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)","volume":"62","author":"Guerrero","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib271","unstructured":"Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04221230 (accessed June 26, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib272","series-title":"Kappa Selective Opioid Receptor Antagonist","author":"Buezo","year":"2009"},{"key":"10.1016\/j.ejmech.2022.114785_bib273","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/jm200789r","article-title":"Discovery of aminobenzyloxyarylamides as \u03ba opioid receptor selective antagonists: application to preclinical development of a \u03ba opioid receptor antagonist receptor occupancy tracer","volume":"54","author":"Mitch","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib274","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib275","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcph.286","article-title":"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects","volume":"54","author":"Lowe","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib276","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/npp.2017.205","article-title":"Repeated administration of opra kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib277","article-title":"A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior, Addict","volume":"25","author":"Jones","year":"2020","journal-title":"Biol."},{"key":"10.1016\/j.ejmech.2022.114785_bib278","unstructured":"Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a (FASTMAS_Kor2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02218736 (accessed June 26, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib279","unstructured":"Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02800928 (accessed June 26, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib280","unstructured":"Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (RAPID KOR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01913535 (accessed June 17, 2020)."},{"key":"10.1016\/j.ejmech.2022.114785_bib281","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1021\/jm2006035","article-title":"Design and discovery of a selective small molecule \u03ba opioid antagonist (2-methyl- N -((2\u2032-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)","volume":"54","author":"Verhoest","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib282","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.111.185108","article-title":"Pharmacological characterization of 2-methyl- N -((2\u2032-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for \u03ba-opioid receptors","volume":"339","author":"Grimwood","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib283","unstructured":"A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00956956 (accessed June 26, 2022)."},{"key":"10.1016\/j.ejmech.2022.114785_bib284","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1016\/j.bmcl.2010.07.113","article-title":"Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1, Bioorg","volume":"20","author":"Brugel","year":"2010","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2011.04.017","article-title":"Identification of short-acting \u03ba-opioid receptor antagonists with anxiolytic-like activity","volume":"661","author":"Peters","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib286","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7164\/antibiotics.55.847","article-title":"CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502","volume":"55","author":"Saito","year":"2002","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2022.114785_bib287","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-0-387-73657-0_121","article-title":"Synthesis of cyclic tetrapeptide CJ 15,208: a novel kappa opioid receptor antagonist","volume":"611","author":"Kulkarni","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2022.114785_bib288","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.bmcl.2009.04.105","article-title":"Nascent structure\u2013activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208, Bioorg","volume":"19","author":"Dolle","year":"2009","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib289","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.tetlet.2010.07.086","article-title":"Synthesis of CJ-15,208, a novel \u03ba-opioid receptor antagonist","volume":"51","author":"Ross","year":"2010","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib290","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2011.01544.x","article-title":"Novel opioid cyclic tetrapeptides: trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting \u03ba opioid receptor antagonism","volume":"165","author":"Ross","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib291","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bph.12132","article-title":"The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting \u03ba opioid receptor antagonism in the CNS after oral administration","volume":"169","author":"Eans","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib292","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0028-3908(80)90190-2","article-title":"Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels","volume":"19","author":"Euvrard","year":"1980","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib293","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0028-3908(91)90068-M","article-title":"The dopamine D2 agonists RU 24213 and RU 24926 are also KAPPA-opioid receptor antagonists","volume":"30","author":"Fortin","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.114785_bib294","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1472-8206.1995.tb00274.x","article-title":"Analgesic effect of the direct D 2 dopamine receptor agonist RU 24926 and cross tolerance with morphine","volume":"9","author":"Suaudeau","year":"1995","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00210-007-0146-x","article-title":"The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone","volume":"375","author":"Beattie","year":"2007","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114785_bib296","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/jpet.300.1.118","article-title":"Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial","volume":"300","author":"Yuan","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114785_bib297","first-page":"247","article-title":"Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation","volume":"4","author":"Deibert","year":"2010","journal-title":"Core Evid."},{"key":"10.1016\/j.ejmech.2022.114785_bib298","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200169","article-title":"Opioid ligands addressing unconventional binding sites and more than one opioid receptor subtype","volume":"17","author":"Drakopoulos","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114785_bib299","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/jm034234f","article-title":"A bivalent ligand (KDAN-18) containing \u03b4-antagonist and \u03ba-agonist pharmacophores bridges \u03b4 2 and \u03ba 1 opioid receptor phenotypes","volume":"48","author":"Daniels","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114785_bib300","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1016\/j.bmcl.2009.10.045","article-title":"A bivalent ligand (KMN-21) antagonist for \u03bc\/\u03ba heterodimeric opioid receptors","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114785_bib301","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1073\/pnas.1016277108","article-title":"N -naphthoyl-\u03b2-naltrexamine (NNTA), a highly selective and potent activator of \u03bc\/\u03ba-opioid heteromers","volume":"108","author":"Yekkirala","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422006870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422006870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:51:49Z","timestamp":1759330309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422006870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":301,"alternative-id":["S0223523422006870"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114785","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2022-s3d4b","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114785"}}